Understand the source comparison
SLU-PP-332 Dosage and Muscle Performance: Product Comparison
This table compares SLU-PP-332 dosing characteristics with alternative research compounds targeting mitochondrial biogenesis and oxidative metabolism. SLU-PP-332 REV-ERBα/β agonist 10–30 mg/kg daily 1.6–4.8 mg/kg (112–336 mg/day) 4–8 weeks for peak effect 70%
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table compares SLU-PP-332 dosing characteristics with alternative research compounds targeting mitochondrial biogenesis and oxidative metabolism.
- SLU-PP-332
- REV-ERBα/β agonist
- 10–30 mg/kg daily
- 1.6–4.8 mg/kg (112–336 mg/day)
- 4–8 weeks for peak effect
- 70% endurance improvement at 30 mg/kg
- Best-in-class for oxidative capacity without stimulant effects—requires sustained dosing
- GW501516 (Cardarine)
- PPARδ agonist
- 2.5–10 mg/kg daily
- 0.4–1.6 mg/kg (28–112 mg/day)
- 2–4 weeks
- 68% endurance improvement at 10 mg/kg
- Comparable endurance gains, faster onset, but flagged for carcinogenicity in long-term rodent studies
- AICAR
- AMPK activator
- 500 mg/kg (injection)
- 80 mg/kg (5,600 mg/day)
- Acute effects within hours
- 44% endurance improvement (single dose)
- Effective but impractical—human equivalent dose is prohibitively high and requires injection
- SR9009
- REV-ERBα agonist
- 100 mg/kg daily
- 16 mg/kg (1,120 mg/day)
- 1–2 weeks
- 50% endurance improvement
- Similar mechanism to SLU-PP-332 but poor oral bioavailability (<2%)—most effects seen with IP injection
- MK-677 (Ibutamoren)
- Ghrelin receptor agonist
- 1–10 mg/kg daily
- 0.16–1.6 mg/kg (11–112 mg/day)
- 4–12 weeks
- Indirect—increases GH/IGF-1, modest lean mass gain
- Not a direct mitochondrial enhancer—works via anabolic signaling, minimal endurance impact
- SLU-PP-332 stands out for oral bioavailability and absence of acute toxicity signals at effective doses. SLU-PP-332 Peptide from Real Peptides undergoes third-party purity verification and small-batch synthesis to ensure amino-acid sequence fidelity—critical when working with compounds where even minor structural variations alter receptor binding affinity.